Vonoprazan prevents bleeding from endoscopic submucosal dissection‐induced gastric ulcers

Vonoprazan, a potassium‐competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)‐induced gastric ulcers compared with proton pump inhibitors (PPIs).

[1]  H. Miyajima,et al.  Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype , 2016, Alimentary pharmacology & therapeutics.

[2]  G. Sachs,et al.  The binding selectivity of vonoprazan (TAK‐438) to the gastric H+,K+‐ATPase , 2015, Alimentary pharmacology & therapeutics.

[3]  Y. Sakurai,et al.  Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study , 2015, Alimentary pharmacology & therapeutics.

[4]  N. Hiramatsu,et al.  Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis , 2015, Alimentary pharmacology & therapeutics.

[5]  R. Jenkins,et al.  Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects , 2015, Alimentary pharmacology & therapeutics.

[6]  Akiko Okamoto,et al.  Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms: Analysis of 1123 lesions , 2012, Journal of gastroenterology and hepatology.

[7]  N. Yamamichi,et al.  PROSPECTIVE SINGLE‐ARM TRIAL OF TWO‐WEEK RABEPRAZOLE TREATMENT FOR ULCER HEALING AFTER GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION , 2012, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[8]  G. Sachs,et al.  Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438) , 2011, Journal of Pharmacology and Experimental Therapeutics.

[9]  A. Barkun,et al.  Meta‐analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer , 2011, Alimentary pharmacology & therapeutics.

[10]  H. Ogata,et al.  Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia , 2011, Journal of Gastroenterology.

[11]  M. Kajino,et al.  A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals , 2011, Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Chayama,et al.  Clinical validity of endoscopic submucosal dissection for submucosal invasive gastric cancer: a single-center study , 2011, Gastric Cancer.

[13]  N. Uedo,et al.  CURRENT MANAGEMENTS AND OUTCOMES OF PEPTIC AND ARTIFICIAL ULCER BLEEDING IN JAPAN , 2010, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[14]  M. Hara,et al.  Risk factors for complications of endoscopic submucosal dissection in gastric tumors: analysis of 478 lesions , 2009, Journal of Gastroenterology.

[15]  N. Uedo,et al.  Effect of a Proton Pump Inhibitor or an H2-Receptor Antagonist on Prevention of Bleeding From Ulcer After Endoscopic Submucosal Dissection of Early Gastric Cancer: A Prospective Randomized Controlled Trial , 2007, The American Journal of Gastroenterology.

[16]  H. Ono,et al.  ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY GASTRIC CANCER: TECHNICAL FEASIBILITY, OPERATION TIME AND COMPLICATIONS FROM A LARGE CONSECUTIVE SERIES , 2005 .

[17]  T. Arakawa,et al.  Effects of zincl-carnosine on gastric mucosal and cell damage caused by ethanol in rats , 1990, Digestive Diseases and Sciences.

[18]  Katsuya Kobayashi,et al.  THE HEALING PROCESS OF GASTRIC ARTIFICIAL ULCERS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION , 2004 .

[19]  K. Ogawa,et al.  Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers , 2002, Alimentary pharmacology & therapeutics.

[20]  L Rodella,et al.  Risk assessment and prediction of rebleeding in bleeding gastroduodenal ulcer. , 2002, Endoscopy.

[21]  Y. Nakanishi,et al.  Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers , 2000, Gastric Cancer.

[22]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[23]  Osada,et al.  Insulin‐like growth factor I plays a role in gastric wound healing: evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model , 1998, Alimentary pharmacology & therapeutics.

[24]  P D Klein,et al.  Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal Ulcer , 1992, Annals of Internal Medicine.

[25]  A. Walan,et al.  Intravenous omeprazole: effect of a loading dose on 24‐h intragastric pH , 1990, Alimentary pharmacology & therapeutics.

[26]  T. Omae,et al.  Factors influencing the healing rate of gastric ulcer in hospitalised subjects. , 1984, Gut.